Navigation Links
Pharmaceutical Companies On Defense As Post-ACA Implementation Continues
Date:4/22/2013

provider relationships with data sets nationally. It is the first—and only—database of its kind.  In one comprehensive solution, pharmaceutical executives can easily identify the interconnectedness of a particular market, allowing them to save time and make smart decisions. HealthCare Network Manager has a NEW mobile-friendly interface and dynamic search capabilities.

About HealthLeaders-InterStudyHealthLeaders-InterStudy, a Decision Resources Group company, is the authoritative source for managed care data, analysis, and news. HealthLeaders-InterStudy is part of the Market Access Business Unit at Decision Resources Group which also includes Abacus International, Fingertip Formulary, Pinsonault, and PharmaStrat. Find out more at www.hl-isy.com.

About Decision Resources GroupDecision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Lydia Smith

Elizabeth MarshallHealthLeaders-InterStudy

Decision Resources Group 781-993-2594

781-993-2563 lsmith@dresources.com

emarshall@dresources.com


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
2. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
3. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
4. Biopharmaceutical Managed Care Strength Closely Intertwined with Marketplace Success
5. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
6. Comparison of Biopharmaceutical Industry Between China and India 2013
7. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
8. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
9. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
10. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
11. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Financial Highlights f or the ... : Revenues increased 58.1% to $24.2 million ... Net income rose 73.6% to $13.4 million, representing a net margin of 55.5% ... " ) increased to $0.80; Diluted EPS increased to $0.79 ...
... EMERYVILLE, Calif., March 28, 2011 Bionovo, Inc. (Nasdaq: ... and development of safe and effective treatments for women,s health ... Phase 1 clinical trial testing the safety of two doses ... hot flushes (study # MF101-008), also known as "menopausal hot ...
Cached Medicine Technology:Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 2Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 3Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 4Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 5Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 6Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 7Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 8Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 9Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 2Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 3
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
(Date:7/8/2014)... enjoy similar longevity and cardiovascular health as other healthy ... the American Journal of Transplantation . The findings ... and the transplant professionals caring for them. , Over ... aged 55 years and older has become more common. ... heart disease, the removal of a kidney could make ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
(Date:7/8/2014)... Hand hygiene rates were found to be three times ... when there were no auditors present, according to a ... , The study, titled, "Quantification of the Hawthorne effect ... system: a retrospective cohort study," published today on-line in ... first author Dr. Jocelyn Srigley, who did the study ...
(Date:7/8/2014)... biomarker that could give expecting mothers and their doctors ... a pregnant woman may develop preeclampsia, at least as ... is a cardiovascular disorder generally occurring late in pregnancy ... and potentially lifelong risks to both mother and baby. ... urine, and is typically diagnosed in the late second ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... the NFL,s,Chicago Bears will visit hospitalized veterans Tuesday, November ... part of the Disabled American,Veterans (DAV) Celebrity Entertainment Program., ... 2:30 p.m., to honor,veterans for serving our nation by ... day for those who have sacrificed,so much for the ...
... Certification ... Criteria -, ... (CCHIT(sm)) today announced that the,Eclypsis Corporation(R) (Nasdaq: ECLP ), The ... Sunrise Clinical Manager(TM),is CCHIT Certified(sm), and meets the Commission,s newly launched ...
... Care Awareness Week, WASHINGTON, Nov. 5 ... coverage for long-term care expenses,according to new survey ... The survey found that many Baby Boomers have ... have not thought about,long-term care insurance. (Logo: ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today ... 2b clinical trial of the investigational drug, Albuferon ... patients with genotype 1 chronic hepatitis C. The ... groups reported fewer missed days of work and ...
... AEDs available in communities could save hundreds of lives, ... Compared with cardiopulmonary resuscitation (CPR) alone, bystander use of ... than doubles a person,s chances of surviving cardiac arrest ... , The researchers analyzed the cases of ...
... (ACP) today renewed its call on Congress to replace the ... effect Jan. 1 with at least two years of positive ... not make the problem worse in future years. The ... students reacted to the final physician fee schedule published late ...
Cached Medicine News:Health News:Eclipsys Sunrise Acute Care Receives CCHIT Certification 2Health News:Eclipsys Sunrise Acute Care Receives CCHIT Certification 3Health News:Eclipsys Sunrise Acute Care Receives CCHIT Certification 4Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 2Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 3Health News:CPR, Defibrillator Combo Boosts Cardiac Incident Survival 2Health News:Congress called on to replace 'devastating' cuts in Medicare reimbursements by ACP 2
... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
Plastic Citrate Tube, .109M / 3.2%...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: